Literature DB >> 12716387

Increased expression of FLIP, an inhibitor of Fas-mediated apoptosis, in stomach cancer.

Sug Hyung Lee1, Hong Sug Kim, Su Young Kim, Yun-Sil Lee, Won Sang Park, Sang Ho Kim, Jung Young Lee, Nam Jin Yoo.   

Abstract

Despite the cell surface expression of Fas (Apo-1/CD95), many types of tumor cells, including stomach cancer cells, are resistant to Fas-mediated apoptosis, indicating the presence of inactivating mechanisms of Fas signaling. Expression of FLICE-like inhibitory protein (FLIP), one of the inhibitory proteins of Fas-mediated apoptosis, has been reported in several cancer types, but not in stomach cancer. In the present study, we analyzed the expression of Fas and FLIP in 60 advanced gastric adenocarcinomas by immunohistochemistry using a tissue microarray approach. Immunopositivity (defined as >/=30% of the neoplastic cells) was observed for Fas in 58 (97%) and FLIP in 54 (90%) of the 60 cancers. All of the tumors with FLIP immunostaining also showed Fas immunostaining. Loss of cell surface Fas immunostaining, another mechanism of Fas resistance, was observed in 45 tumors (75%). By contrast, normal gastric mucosal cells showed no or weak expression of both Fas and FLIP. Taken together, these results indicate that increased expression of FLIP is a frequent event in stomach carcinomas, and suggest that for evading apoptosis stomach carcinoma cells in vivo may need FLIP expression, which might contribute to tumor development.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12716387     DOI: 10.1034/j.1600-0463.2003.1110203.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  21 in total

1.  Expression of the cellular FLICE-inhibitory protein (c-FLIP) protects Hodgkin's lymphoma cells from autonomous Fas-mediated death.

Authors:  A Dutton; J D O'Neil; A E Milner; G M Reynolds; J Starczynski; J Crocker; L S Young; P G Murray
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-19       Impact factor: 11.205

2.  Fas ligand expression in colon cancer: a possible mechanism of tumor immune privilege.

Authors:  Wei Zhang; Er-Xun Ding; Qiang Wang; Da-Qiao Zhu; Jin He; Yu-Li Li; Yuan-He Wang
Journal:  World J Gastroenterol       Date:  2005-06-21       Impact factor: 5.742

3.  Major histocompatibility complex class II inhibits fas antigen-mediated gastric mucosal cell apoptosis through actin-dependent inhibition of receptor aggregation.

Authors:  Calin Stoicov; Xun Cai; Hanchen Li; Kristine Klucevsek; Jane Carlson; Reza Saffari; Jeanmarie Houghton
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

4.  The TRAIL system is over-expressed in breast cancer and FLIP a marker of good prognosis.

Authors:  Gustav J Ullenhag; Ahmad Al-Attar; Abhik Mukherjee; Andrew R Green; Ian O Ellis; Lindy G Durrant
Journal:  J Cancer Res Clin Oncol       Date:  2014-09-18       Impact factor: 4.553

5.  Fas-mediated apoptosis in cholangiocarcinoma cells is enhanced by 3,3'-diindolylmethane through inhibition of AKT signaling and FLICE-like inhibitory protein.

Authors:  Yabing Chen; Jianmin Xu; Nirag Jhala; Pritish Pawar; Zeng B Zhu; Liping Ma; Chang-Hyun Byon; Jay M McDonald
Journal:  Am J Pathol       Date:  2006-11       Impact factor: 4.307

6.  Expression of c-FLIP in pulmonary metastases in osteosarcoma patients and human xenografts.

Authors:  Krithi Rao-Bindal; Chethan K Rao; Ling Yu; Eugenie S Kleinerman
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

7.  T-bet knockout prevents Helicobacter felis-induced gastric cancer.

Authors:  Calin Stoicov; Xueli Fan; Jian Hua Liu; Glennice Bowen; Mark Whary; Evelyn Kurt-Jones; JeanMarie Houghton
Journal:  J Immunol       Date:  2009-06-17       Impact factor: 5.422

8.  Role of S-nitrosylation in apoptosis resistance and carcinogenesis.

Authors:  Anand Krishnan V Iyer; Neelam Azad; Liying Wang; Yon Rojanasakul
Journal:  Nitric Oxide       Date:  2008-04-24       Impact factor: 4.427

9.  Involvement of FLIP in 2-methoxyestradiol-induced tumor regression in transgenic adenocarcinoma of mouse prostate model.

Authors:  Manonmani Ganapathy; Rita Ghosh; Xie Jianping; Xiaoping Zhang; Roble Bedolla; John Schoolfield; I-Tien Yeh; Dean A Troyer; Aria F Olumi; Addanki P Kumar
Journal:  Clin Cancer Res       Date:  2009-02-17       Impact factor: 12.531

Review 10.  FLIP as an anti-cancer therapeutic target.

Authors:  Jin Kuk Yang
Journal:  Yonsei Med J       Date:  2008-02-29       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.